Delay and restricted access of new molecules in Turkey compared to the United States and European Union

This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007-2013. The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after January 1, 2007, worldwide and marketi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of market access & health policy 2013, Vol.1 (1), p.22799
Main Authors: Şahin, Toros, Yeşil, Atakan, Topcu, Türker
Format: Article
Language:English
Subjects:
access to medicine
Audits
Communication
Data bases
Drug stores
Funding
Good Manufacturing Practice
launch
Marketing
new molecules
Pharmaceutical industry
Price cuts
Product development
Regulation
Regulatory approval
Short Communication
Studies
Turkish pharmaceutical market
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 1
container_start_page 22799
container_title Journal of market access & health policy
container_volume 1
creator Şahin, Toros
Yeşil, Atakan
Topcu, Türker
description This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007-2013. The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after January 1, 2007, worldwide and marketing authorization approval after January 1, 2007, in the European Union. The launch dates for the European Union, the United States, and Turkey were retrieved from the same database. Data for Turkey were confirmed via IMS and RxMedia. Out of 183 records identified that are launched in the European Union, the United States, or both, 44 of the NMs are launched in Turkey (24%). The results of this study show that 24% of the NMs that are launched in either the European Union or United States were able to be launched in Turkey with a mean delay of 821 days (2.25 years).
doi_str_mv 10.3402/jmahp.v1i0.22799
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_27226824</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3920931171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3449-609a697795fe6d4e1782628eaf90c52a04f73952e7c49a2cc5f53831b4fe28983</originalsourceid><addsrcrecordid>eNp1kcFrFTEQh4MottTePUnAi5f3zCbZzQZBkLa2QsGD7TlMs5O-PHeTNdltef-92b5aquApCfPNx0x-hLyt2FpIxj9uB9iM67vKszXnSusX5JAzVq2aptUvn90PyHHOW1aeQnKm6tfkgCvOm5bLQ3J7ij3sKISOJsxT8nbCjoK1mDONjga8p0Ps0c49ZuoDvZrTT9xRG4cRUkGnSKcN0uvgl8YfE0yFW3Rnc4ojQlhKMbwhrxz0GY8fzyNy_fXs6uRidfn9_NvJl8uVFVLqVcM0NFopXTtsOomVannDWwSnma05MOmU0DVHZaUGbm3tatGK6kY65K1uxRH5vPeO882AncUwJejNmPwAaWciePN3JfiNuY13RrZNrSQvgg-PghR_zeVLzOCzxb6HgHHOplKaC6WrVhT0_T_oNs4plPUKVRcd03qh2J6yKeac0D0NUzGzBGkegjRLkOYhyNLy7vkSTw1_YivApz3gg4tpgPuY-s5MsOtjcgmC9dmI_-p_A8w2r6w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1756570993</pqid></control><display><type>article</type><title>Delay and restricted access of new molecules in Turkey compared to the United States and European Union</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Taylor &amp; Francis Open Access</source><source>PubMed Central Free</source><source>PAIS Index</source><creator>Şahin, Toros ; Yeşil, Atakan ; Topcu, Türker</creator><creatorcontrib>Şahin, Toros ; Yeşil, Atakan ; Topcu, Türker</creatorcontrib><description>This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007-2013. The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after January 1, 2007, worldwide and marketing authorization approval after January 1, 2007, in the European Union. The launch dates for the European Union, the United States, and Turkey were retrieved from the same database. Data for Turkey were confirmed via IMS and RxMedia. Out of 183 records identified that are launched in the European Union, the United States, or both, 44 of the NMs are launched in Turkey (24%). The results of this study show that 24% of the NMs that are launched in either the European Union or United States were able to be launched in Turkey with a mean delay of 821 days (2.25 years).</description><identifier>ISSN: 2001-6689</identifier><identifier>EISSN: 2001-6689</identifier><identifier>DOI: 10.3402/jmahp.v1i0.22799</identifier><identifier>PMID: 27226824</identifier><language>eng</language><publisher>United States: Routledge</publisher><subject>access to medicine ; Audits ; Communication ; Data bases ; Drug stores ; Funding ; Good Manufacturing Practice ; launch ; Marketing ; new molecules ; Pharmaceutical industry ; Price cuts ; Product development ; Regulation ; Regulatory approval ; Short Communication ; Studies ; Turkish pharmaceutical market</subject><ispartof>Journal of market access &amp; health policy, 2013, Vol.1 (1), p.22799</ispartof><rights>2013 Toros Şahin et al. 2013</rights><rights>Copyright Co-Action Publishing 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1756570993/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1756570993?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,25753,27502,27866,27923,27924,27925,37012,37013,44590,53791,53793,59143,59144,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27226824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Şahin, Toros</creatorcontrib><creatorcontrib>Yeşil, Atakan</creatorcontrib><creatorcontrib>Topcu, Türker</creatorcontrib><title>Delay and restricted access of new molecules in Turkey compared to the United States and European Union</title><title>Journal of market access &amp; health policy</title><addtitle>J Mark Access Health Policy</addtitle><description>This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007-2013. The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after January 1, 2007, worldwide and marketing authorization approval after January 1, 2007, in the European Union. The launch dates for the European Union, the United States, and Turkey were retrieved from the same database. Data for Turkey were confirmed via IMS and RxMedia. Out of 183 records identified that are launched in the European Union, the United States, or both, 44 of the NMs are launched in Turkey (24%). The results of this study show that 24% of the NMs that are launched in either the European Union or United States were able to be launched in Turkey with a mean delay of 821 days (2.25 years).</description><subject>access to medicine</subject><subject>Audits</subject><subject>Communication</subject><subject>Data bases</subject><subject>Drug stores</subject><subject>Funding</subject><subject>Good Manufacturing Practice</subject><subject>launch</subject><subject>Marketing</subject><subject>new molecules</subject><subject>Pharmaceutical industry</subject><subject>Price cuts</subject><subject>Product development</subject><subject>Regulation</subject><subject>Regulatory approval</subject><subject>Short Communication</subject><subject>Studies</subject><subject>Turkish pharmaceutical market</subject><issn>2001-6689</issn><issn>2001-6689</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>7TQ</sourceid><sourceid>PIMPY</sourceid><recordid>eNp1kcFrFTEQh4MottTePUnAi5f3zCbZzQZBkLa2QsGD7TlMs5O-PHeTNdltef-92b5aquApCfPNx0x-hLyt2FpIxj9uB9iM67vKszXnSusX5JAzVq2aptUvn90PyHHOW1aeQnKm6tfkgCvOm5bLQ3J7ij3sKISOJsxT8nbCjoK1mDONjga8p0Ps0c49ZuoDvZrTT9xRG4cRUkGnSKcN0uvgl8YfE0yFW3Rnc4ojQlhKMbwhrxz0GY8fzyNy_fXs6uRidfn9_NvJl8uVFVLqVcM0NFopXTtsOomVannDWwSnma05MOmU0DVHZaUGbm3tatGK6kY65K1uxRH5vPeO882AncUwJejNmPwAaWciePN3JfiNuY13RrZNrSQvgg-PghR_zeVLzOCzxb6HgHHOplKaC6WrVhT0_T_oNs4plPUKVRcd03qh2J6yKeac0D0NUzGzBGkegjRLkOYhyNLy7vkSTw1_YivApz3gg4tpgPuY-s5MsOtjcgmC9dmI_-p_A8w2r6w</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Şahin, Toros</creator><creator>Yeşil, Atakan</creator><creator>Topcu, Türker</creator><general>Routledge</general><general>Taylor &amp; Francis Ltd</general><general>Co-Action Publishing</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TQ</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DHY</scope><scope>DON</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M0T</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2013</creationdate><title>Delay and restricted access of new molecules in Turkey compared to the United States and European Union</title><author>Şahin, Toros ; Yeşil, Atakan ; Topcu, Türker</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3449-609a697795fe6d4e1782628eaf90c52a04f73952e7c49a2cc5f53831b4fe28983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>access to medicine</topic><topic>Audits</topic><topic>Communication</topic><topic>Data bases</topic><topic>Drug stores</topic><topic>Funding</topic><topic>Good Manufacturing Practice</topic><topic>launch</topic><topic>Marketing</topic><topic>new molecules</topic><topic>Pharmaceutical industry</topic><topic>Price cuts</topic><topic>Product development</topic><topic>Regulation</topic><topic>Regulatory approval</topic><topic>Short Communication</topic><topic>Studies</topic><topic>Turkish pharmaceutical market</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Şahin, Toros</creatorcontrib><creatorcontrib>Yeşil, Atakan</creatorcontrib><creatorcontrib>Topcu, Türker</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>PAIS Index</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of market access &amp; health policy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Şahin, Toros</au><au>Yeşil, Atakan</au><au>Topcu, Türker</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Delay and restricted access of new molecules in Turkey compared to the United States and European Union</atitle><jtitle>Journal of market access &amp; health policy</jtitle><addtitle>J Mark Access Health Policy</addtitle><date>2013</date><risdate>2013</risdate><volume>1</volume><issue>1</issue><spage>22799</spage><pages>22799-</pages><issn>2001-6689</issn><eissn>2001-6689</eissn><abstract>This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007-2013. The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after January 1, 2007, worldwide and marketing authorization approval after January 1, 2007, in the European Union. The launch dates for the European Union, the United States, and Turkey were retrieved from the same database. Data for Turkey were confirmed via IMS and RxMedia. Out of 183 records identified that are launched in the European Union, the United States, or both, 44 of the NMs are launched in Turkey (24%). The results of this study show that 24% of the NMs that are launched in either the European Union or United States were able to be launched in Turkey with a mean delay of 821 days (2.25 years).</abstract><cop>United States</cop><pub>Routledge</pub><pmid>27226824</pmid><doi>10.3402/jmahp.v1i0.22799</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2001-6689
ispartof Journal of market access & health policy, 2013, Vol.1 (1), p.22799
issn 2001-6689
2001-6689
language eng
recordid cdi_pubmed_primary_27226824
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); Taylor & Francis Open Access; PubMed Central Free; PAIS Index
subjects access to medicine
Audits
Communication
Data bases
Drug stores
Funding
Good Manufacturing Practice
launch
Marketing
new molecules
Pharmaceutical industry
Price cuts
Product development
Regulation
Regulatory approval
Short Communication
Studies
Turkish pharmaceutical market
title Delay and restricted access of new molecules in Turkey compared to the United States and European Union
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A32%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Delay%20and%20restricted%20access%20of%20new%20molecules%20in%20Turkey%20compared%20to%20the%20United%20States%20and%20European%20Union&rft.jtitle=Journal%20of%20market%20access%20&%20health%20policy&rft.au=%C5%9Eahin,%20Toros&rft.date=2013&rft.volume=1&rft.issue=1&rft.spage=22799&rft.pages=22799-&rft.issn=2001-6689&rft.eissn=2001-6689&rft_id=info:doi/10.3402/jmahp.v1i0.22799&rft_dat=%3Cproquest_pubme%3E3920931171%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3449-609a697795fe6d4e1782628eaf90c52a04f73952e7c49a2cc5f53831b4fe28983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1756570993&rft_id=info:pmid/27226824&rfr_iscdi=true